07:00 , Apr 29, 2013 |  BC Week In Review  |  Financial News

Acumen Pharmaceuticals completes venture financing

Acumen Pharmaceuticals Inc. , Livermore, Calif.   Business: Neurology   Date completed: 4/25/13   Type: Venture financing   Raised: Not disclosed   Investors: BVF Partners; NeuroVentures; Praxis Technologies; Glynn Ventures; private investors   Note: Acumen...
01:04 , Apr 26, 2013 |  BC Extra  |  Financial News

Acumen announces first close of $20 million series A

Acumen Pharmaceuticals Inc. (Livermore, Calif.) raised an undisclosed amount in the first close of a $20 million series A financing led by existing investor BVF Partners. Existing investor NeuroVentures also participated, along with Praxis Technologies;...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

Acumen Pharmaceuticals, Merck deal

Acumen said Merck terminated an amended 2003 deal and returned rights to develop and commercialize anti-amyloid-derived diffusible ligand (ADDL) antibody therapeutics and diagnostics for Alzheimer's disease. According to Acumen, Merck made the decision based on...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

Acumen Pharmaceuticals management update

Acumen Pharmaceuticals Inc. , Livermore, Calif.   Business: Neurology   Hired: Franz Hefti, a director, as president and CEO, formerly chief science officer at Avid Radiopharmaceuticals Inc. , which Eli Lilly and Co. acquired; he...
01:21 , Dec 22, 2011 |  BC Extra  |  Company News

Merck ends AD deal with Acumen

Acumen Pharmaceuticals Inc. (Livermore, Calif.) said Merck & Co. Inc. (NYSE:MRK) terminated a 2003 deal and returned rights to develop and commercialize anti-amyloid-derived diffusible ligand (ADDL) antibody therapeutics and diagnostics for Alzheimer's disease. According to...
08:00 , Feb 12, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Insulin receptor (INSR); b-amyloid (Ab) In vitro studies suggest that boosting brain insulin signaling could help slow or...
08:00 , Jan 29, 2007 |  BC Week In Review  |  Company News

Acumen Pharmaceuticals, Merck deal

Acumen received a $5 million milestone payment under a 2004 deal that was amended in 2006, which gives MRK exclusive worldwide rights to develop MAbs, vaccines and diagnostics against amyloid-derived diffusible ligand (ADDL) for Alzheimer's...
08:00 , Dec 4, 2006 |  BC Week In Review  |  Company News

Acumen Pharmaceuticals, Merck deal

The companies amended a 2004 agreement, giving MRK exclusive R&D rights to diagnostic products directed at amyloid-derived diffusible ligands (ADDLs). All other rights in the original agreement remain unchanged, including MRK's exclusive worldwide rights to...
08:00 , Nov 13, 2006 |  BC Week In Review  |  Company News

Acumen Pharmaceuticals Inc. management update

Acumen Pharmaceuticals Inc. , South San Francisco, Calif.   Business: Neurology   Promoted: William Goure to COO from VP of business development  ...
07:00 , May 30, 2005 |  BioCentury  |  Finance

VPOs into the breach

Biotech startups have been complaining that the venture community is less willing to fund very early stage technologies than in the past. As a result, there is a gap between academic discoveries and the translational...